Paper32165486
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Li X and 17 others. Haematologica, 2021. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Papers, record 32165486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32165486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Animals | |
| Apoptosis | |
| Bridged Bicyclo Compounds, Heterocyclic | |
| Cell Line, Tumor | |
| Humans | |
| Mice | |
| Morpholines | |
| Pyrimidines | |
| Sulfonamides | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA022453 | NCI NIH HHS | United States | P30CA022453 | PubMed and NIH | NIH RePORTER |
| T32 CA009531 | NCI NIH HHS | United States | T32CA009531 | PubMed and NIH | NIH RePORTER |
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30668936 | A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. | Biochem Pharmacol | 2019 | https://conductscience.org/library/papers/30668936 | PubMed |
| 2 | 19805519 | Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. | Mol Cell Biol | 2009 | https://conductscience.org/library/papers/19805519 | PubMed |
| 3 | 22693356 | Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22693356 | PubMed |
| 4 | 24890832 | MYC activation is a hallmark of cancer initiation and maintenance. | Cold Spring Harb Perspect Med | 2014 | https://conductscience.org/library/papers/24890832 | PubMed |
| 5 | 29666304 | Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29666304 | PubMed |
| 6 | 27980108 | Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/27980108 | PubMed |
| 7 | 21901171 | Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. | Genes Cancer | 2011 | https://conductscience.org/library/papers/21901171 | PubMed |
| 8 | 30596398 | Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. | J Cell Mol Med | 2018 | https://conductscience.org/library/papers/30596398 | PubMed |
| 9 | 18288131 | Cooperating gene mutations in acute myeloid leukemia: a review of the literature. | Leukemia | 2008 | https://conductscience.org/library/papers/18288131 | PubMed |
| 10 | 25308513 | Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. | Mol Oncol | 2015 | https://conductscience.org/library/papers/25308513 | PubMed |
| 11 | 20889917 | Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20889917 | PubMed |
| 12 | 24909171 | Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. | Oncogene | 2015 | https://conductscience.org/library/papers/24909171 | PubMed |
| 13 | 28176818 | Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. | Sci Rep | 2017 | https://conductscience.org/library/papers/28176818 | PubMed |
| 14 | 27103402 | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27103402 | PubMed |
| 15 | 30819918 | Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. | Haematologica | 2019 | https://conductscience.org/library/papers/30819918 | PubMed |
| 16 | 25916698 | Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. | Leuk Res | 2015 | https://conductscience.org/library/papers/25916698 | PubMed |
| 17 | 24531733 | Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. | Leukemia | 2014 | https://conductscience.org/library/papers/24531733 | PubMed |
| 18 | 27601886 | Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. | Patient Prefer Adherence | 2016 | https://conductscience.org/library/papers/27601886 | PubMed |
| 19 | 27166183 | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27166183 | PubMed |
| 20 | 27049457 | Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27049457 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985246 | The utility of pyrimidine derivatives in the construction of five-membered non-azole-fused [d]pyrimidines: part III-synthetic strategies and biological applications. | RSC Adv | 2026 | https://conductscience.org/library/papers/42985246 | PubMed |
| 42684666 | Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability. | BioDrugs | 2026 | https://conductscience.org/library/papers/42684666 | PubMed |
| 42318952 | PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. | Oncol Rep | 2026 | https://conductscience.org/library/papers/42318952 | PubMed |
| 40701845 | Fimepinostat is a dual inhibitor of tumor and angiogenesis in glioblastoma and synergizes with temozolomide through suppressing MYC. | Korean J Physiol Pharmacol | 2025 | https://conductscience.org/library/papers/40701845 | PubMed |
| 40695793 | Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40695793 | PubMed |
| 40478628 | Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40478628 | PubMed |
| 39869284 | Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/39869284 | PubMed |
| 39780285 | ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39780285 | PubMed |
| 39334157 | NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia. | J Transl Med | 2024 | https://conductscience.org/library/papers/39334157 | PubMed |
| 39035053 | The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia. | Pathol Oncol Res | 2024 | https://conductscience.org/library/papers/39035053 | PubMed |
| 38373594 | Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax. | Biochem Pharmacol | 2024 | https://conductscience.org/library/papers/38373594 | PubMed |
| 38266099 | The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia. | Cancer Res | 2024 | https://conductscience.org/library/papers/38266099 | PubMed |
| 38148433 | Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells. | Med Oncol | 2023 | https://conductscience.org/library/papers/38148433 | PubMed |
| 38085423 | Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage. | Invest New Drugs | 2024 | https://conductscience.org/library/papers/38085423 | PubMed |
| 36895970 | A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/36895970 | PubMed |
| 36765741 | Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765741 | PubMed |
| 36316313 | Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/36316313 | PubMed |
| 36313732 | Mechanisms of venetoclax resistance and solutions. | Front Oncol | 2022 | https://conductscience.org/library/papers/36313732 | PubMed |
| 36208684 | Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia. | Biochem Pharmacol | 2022 | https://conductscience.org/library/papers/36208684 | PubMed |
| 36171897 | The role of protein acetylation in carcinogenesis and targeted drug discovery. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36171897 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32165486
GET https://conductscience.org/api/papers/v1/32165486/references?page=2